PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 16158823-8 2005 We first treated the patient with fludarabine and then with the CHOP regimen (cyclophosphamide, hydroxydaunomycin, vincristine [Oncovin], and prednisone), but the disease was so refractory that the patient died of the disease 13 months after the splenectomy. Cyclophosphamide 78-94 DNA damage inducible transcript 3 Homo sapiens 64-68 16831024-5 2006 The combination of rituximab with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) was cost effective as first-line therapy for advanced-stage diffuse large B-cell NHL compared with CHOP alone. Cyclophosphamide 34-50 DNA damage inducible transcript 3 Homo sapiens 93-97 16331635-2 2006 Attempts to improve the results achieved with the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) using second-generation or third-generation chemotherapy have failed. Cyclophosphamide 65-81 DNA damage inducible transcript 3 Homo sapiens 125-129 16706552-5 2006 The combination of rituximab with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) was cost effective as first-line therapy for advanced-stage diffuse large B-cell NHL compared with CHOP alone. Cyclophosphamide 34-50 DNA damage inducible transcript 3 Homo sapiens 93-97 16575475-1 2006 Authors conducted a one-year prospective study to determine whether CHOP regimen (cyclophosphamide, doxorubicin, vincristin, and prednisone), used in the treatment of aggressive non-Hodgkin s lymphoma, is associated with the presence of an early impairment of cardiac function. Cyclophosphamide 82-98 DNA damage inducible transcript 3 Homo sapiens 68-72 16123223-0 2005 Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Cyclophosphamide 61-77 DNA damage inducible transcript 3 Homo sapiens 121-125 15914552-1 2005 The addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy results in significant improvement in clinical outcome for individuals with non-HIV-associated aggressive B-cell lymphoma. Cyclophosphamide 29-45 DNA damage inducible transcript 3 Homo sapiens 89-93 15955905-1 2005 PURPOSE: For more than two decades, cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) has been the standard therapy for diffuse large B-cell lymphoma (DLBCL). Cyclophosphamide 36-52 DNA damage inducible transcript 3 Homo sapiens 96-100 16006279-1 2005 Treatment of non-Hodgkin"s lymphoma with the CHOP regimen consists of intravenous cyclophosphamide 750 mg/m2 (day 1), intravenous doxorubicin 50 mg/m2 (day 1), intravenous vincristine 1.4 mg/m2 (day 1), and oral prednisone 100 mg (days 1-5). Cyclophosphamide 82-98 DNA damage inducible transcript 3 Homo sapiens 45-49 15034757-7 2004 Treatment with high-dose corticosteroids was initiated, with clinical improvement, and was immediately followed by therapy with cyclophosphamide, hydroxydaunomycin, vincristine, and prednisone (CHOP), which induced complete remission with a follow-up of 1 year. Cyclophosphamide 128-144 DNA damage inducible transcript 3 Homo sapiens 194-198 15791475-3 2005 The patient was treated for diffuse large B-cell non-Hodgkin"s lymphoma with CHOP therapy (doxorubicin, cyclophosphamide, vincristine, and prednisone). Cyclophosphamide 104-120 DNA damage inducible transcript 3 Homo sapiens 77-81 15666323-1 2005 BACKGROUND: The standard treatment for patients with aggressive non-Hodgkin lymphoma (NHL) is cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). Cyclophosphamide 94-110 DNA damage inducible transcript 3 Homo sapiens 154-158 15794864-2 2005 Cyclophosphamide/doxorubicin/vincristine/prednisone/rituximab (CHOP-R) is a stem cellsparing regimen that has been extensively evaluated in patients without WM or non-Hodgkin"s lymphoma. Cyclophosphamide 0-16 DNA damage inducible transcript 3 Homo sapiens 63-67 15621841-5 2005 The patient responded to chemotherapy with CHOP (doxorubicin, cyclophosphamide, vincristine and prednisone) therapy, with disappearance of the abnormal clone from the bone marrow. Cyclophosphamide 62-78 DNA damage inducible transcript 3 Homo sapiens 43-47 14982884-1 2004 The combination of cyclophosphamide, doxorubicin, vincristine, and prednisone, given every 3 weeks (CHOP-21) is standard chemotherapy for aggressive lymphomas. Cyclophosphamide 19-35 DNA damage inducible transcript 3 Homo sapiens 100-104 15918208-2 2005 The patient was successfully treated with a first generation therapy, CHOP modified regimen (cyclophosphamide 600 mg/m2 intravenously on d 1, epirubicin 55 mg/m2 intravenously on d 1, vincristine 1.2 mg/m2 intravenously on d 1, prednisone 60 mg/m2 on d 1-5), and a complete response was achieved. Cyclophosphamide 93-109 DNA damage inducible transcript 3 Homo sapiens 70-74 15921395-2 2005 In this study we found that HIV-infected patients with diffuse large B-cell lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone (CHOP) and HAART showed a similar response rate to chemotherapy, disease-free survival and overall survival as those of HIV-negative patients receiving CHOP. Cyclophosphamide 98-114 DNA damage inducible transcript 3 Homo sapiens 164-168 15550586-1 2004 BACKGROUND: We demonstrated that highly active antiretroviral therapy (HAART) increases the toxic effect of cyclophosphamide, vincristine, doxorubicin (DOX) and prednisone (CHOP) in HIV-patients with non-Hodgkin"s lymphoma (NHL). Cyclophosphamide 108-124 DNA damage inducible transcript 3 Homo sapiens 173-177 15626054-10 2004 Cyclophosphamide, doxorubicin, vincristine and prednisone, (CHOP) chemotherapy was given to 68.7% of the patients with complete remission rates of 55.6% for those who got a minimum of six courses of chemotherapy. Cyclophosphamide 0-16 DNA damage inducible transcript 3 Homo sapiens 60-64 15016643-1 2004 Cyclophosphamide, doxorubicin, vincristine, and prednisone, given every 3 weeks (CHOP-21), is standard chemotherapy for aggressive lymphomas. Cyclophosphamide 0-16 DNA damage inducible transcript 3 Homo sapiens 81-85 15205203-2 2004 Recently, chemotherapy consisting of doxorubicin, cyclophosphamide, vincristine and prednisone (CHOP) has been reported as effective treatment for early-stage gastric DLBCL. Cyclophosphamide 50-66 DNA damage inducible transcript 3 Homo sapiens 96-100 28140109-1 2004 In the past, CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone) was considered the gold standard treatment for aggressive non-Hodgkin"s lymphoma (NHL). Cyclophosphamide 32-48 DNA damage inducible transcript 3 Homo sapiens 13-17 15181605-5 2004 In patients with aggressive lymphoma who receive cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy, 40% to 70% of patients attain a complete remission, depending on risk factors such as age and extranodal involvement. Cyclophosphamide 49-65 DNA damage inducible transcript 3 Homo sapiens 109-113 15060745-2 2004 The risk is significantly evident in patients with aggressive lymphoma, which is highly responsive to standard chemotherapy with cyclophosphamide, hydroxydaunomycin, vincristine, and prednisone (CHOP) achieving a complete response rate of 60-80% and 5-year survival rate of 30-50% with only 1% of treatment-related mortality. Cyclophosphamide 129-145 DNA damage inducible transcript 3 Homo sapiens 195-199 15042528-1 2004 In the past, CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone) was considered the gold standard treatment for aggressive non-Hodgkin"s lymphoma (NHL). Cyclophosphamide 32-48 DNA damage inducible transcript 3 Homo sapiens 13-17 14752912-4 2004 Current chemotherapy of choice is CHOP [Cyclophosphamide, Hydroxydaunomycin (doxorubicin), Oncovin (vincristine sulfate) and Prednisone]. Cyclophosphamide 40-56 DNA damage inducible transcript 3 Homo sapiens 34-38 12915593-1 2003 PURPOSE: To investigate whether the relative dose-intensity of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy could be improved by prophylactic administration of granulocyte colony-stimulating factor (G-CSF) in elderly patients with aggressive non-Hodgkin"s lymphoma (NHL). Cyclophosphamide 63-79 DNA damage inducible transcript 3 Homo sapiens 123-127 14513044-1 2003 For the last decade, cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) has been the best available standard of care for aggressive non-Hodgkin"s lymphoma (NHL), based on equivalent therapeutic results with other multiagent chemotherapy accompanied by lower costs and lesser toxicity. Cyclophosphamide 21-37 DNA damage inducible transcript 3 Homo sapiens 81-85 14581895-1 2003 BACKGROUND: Six to eight cycles of CHOP therapy (cyclophosphamide, doxorubicin, vincristine, and prednisone) is standard for intermediate-grade non-Hodgkin"s lymphoma (NHL) but is associated with toxicity that may cause premature termination of therapy. Cyclophosphamide 49-65 DNA damage inducible transcript 3 Homo sapiens 35-39 12931670-4 2003 Prior to pathological diagnosis, CHOP therapy with cyclophosphamide, adriamycin, vincristine and prednisolone was performed under mechanical ventilation for the purpose of resuscitation. Cyclophosphamide 51-67 DNA damage inducible transcript 3 Homo sapiens 33-37 12955576-4 2003 A recent European phase III study in elderly patients with untreated diffuse large B-cell lymphoma suggested that rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) chemotherapy is superior to CHOP chemotherapy alone in terms of complete response rate and event-free and overall survivals. Cyclophosphamide 129-145 DNA damage inducible transcript 3 Homo sapiens 191-195 12955576-4 2003 A recent European phase III study in elderly patients with untreated diffuse large B-cell lymphoma suggested that rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) chemotherapy is superior to CHOP chemotherapy alone in terms of complete response rate and event-free and overall survivals. Cyclophosphamide 129-145 DNA damage inducible transcript 3 Homo sapiens 225-229 12906019-2 2003 The first-line treatment for diffuse large-B-cell non Hodgkin"s lymphoma, a highly malignant lymphoma, is CHOP chemotherapy (cyclophosphamide + doxorubicin + vincristine + prednisone). Cyclophosphamide 125-141 DNA damage inducible transcript 3 Homo sapiens 106-110 12764549-9 2003 Cyclophosphamide, hydroxydaunomycin, vincristine, and prednisone (CHOP)-like chemotherapy with or without local irradiation led to 17% relapses in patients with localized aggressive lymphoma. Cyclophosphamide 0-16 DNA damage inducible transcript 3 Homo sapiens 66-70 12956443-10 2003 In this study, the t(11;16) was seen in 2 patients with previous lymphomas treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). Cyclophosphamide 88-104 DNA damage inducible transcript 3 Homo sapiens 148-152 12521569-9 2003 For diffuse large B-cell lymphoma, the most frequently diagnosed subtype of non-Hodgkin"s lymphoma (NHL), the CHOP regimen (cyclophosphamide, doxorubicin, vincristine, and prednisone) is still the gold standard. Cyclophosphamide 124-140 DNA damage inducible transcript 3 Homo sapiens 110-114 14653077-5 2003 The CR rate and 5-year survival rate of patients who were treated by the scheme of doxorubicin, cyclophosphamide, vincristine and prednisone (CHOP) were higher than those treated by the scheme of cyclophosphamide, vincristine, prednisone and etoposide (COP + VP16) (P < 0.05). Cyclophosphamide 96-112 DNA damage inducible transcript 3 Homo sapiens 142-146 12707721-2 2003 During pregnancy chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) stabilized the disease for 4 months before new manifestations appeared. Cyclophosphamide 35-51 DNA damage inducible transcript 3 Homo sapiens 95-99 12490805-7 2002 Eventually the patient responded to CHOP (cyclophosphamide, Oncovin [vincristine, Eli Lilly, Indianapolis, IN], prednisone, and doxorubicin) therapy. Cyclophosphamide 42-58 DNA damage inducible transcript 3 Homo sapiens 36-40 14988743-10 2003 Impressive results have been seen in combination with CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine and prednisone) in follicular and high-grade lymphomas. Cyclophosphamide 73-89 DNA damage inducible transcript 3 Homo sapiens 54-58 12479593-3 2002 The gold standard for primary treatment of aggressive NHL is combination chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP). Cyclophosphamide 91-107 DNA damage inducible transcript 3 Homo sapiens 150-154 12176789-1 2002 BACKGROUND: Recent data suggest that chemotherapy with the cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) regimen is a highly effective treatment for localised primary gastric lymphoma of diffuse large B-cell histology (DLBCL). Cyclophosphamide 59-75 DNA damage inducible transcript 3 Homo sapiens 118-122 11807147-1 2002 BACKGROUND: The standard treatment for patients with diffuse large-B-cell lymphoma is cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). Cyclophosphamide 86-102 DNA damage inducible transcript 3 Homo sapiens 146-150 12710585-5 2002 The most significant of these strategies is the combination of rituximab and CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine and prednisone), which is proving a highly effective combination in the treatment of NHL. Cyclophosphamide 96-112 DNA damage inducible transcript 3 Homo sapiens 77-81 12710590-1 2002 The standard therapy for patients with aggressive lymphoma is cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy, which achieves a complete response in more than 60% of patients but is curative in only about 40-50%. Cyclophosphamide 62-78 DNA damage inducible transcript 3 Homo sapiens 121-125 12533055-2 2002 A 43-year-old female with DLCL, who relapsed after first line chemotherapy (CHOP--cyclophosphamide, doxorubicin, vincristine, and prednisone) and progressed despite salvage chemotherapy (EPOCH-etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin), was treated effectively with 8 cycles of Rituximab. Cyclophosphamide 82-98 DNA damage inducible transcript 3 Homo sapiens 76-80 12091638-20 2002 The CHOP regimen is cyclophosphamide, doxorubicine, vincristine and prednisone. Cyclophosphamide 20-36 DNA damage inducible transcript 3 Homo sapiens 4-8 11878581-1 2001 PURPOSE: The authors report the use of a cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone (CHOP)-based chemotherapy regimen in treating six children with posttransplantation lymphoproliferative disorder (PTLD) that developed after solid organ transplantation. Cyclophosphamide 41-57 DNA damage inducible transcript 3 Homo sapiens 109-113 11584710-9 2001 Standard treatment of advanced aggressive NHL is polychemotherapy with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP). Cyclophosphamide 71-87 DNA damage inducible transcript 3 Homo sapiens 129-133 11276342-6 2001 The patient was treated with combination chemotherapy, including cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP), which resulted in complete clinical remission after two courses. Cyclophosphamide 65-81 DNA damage inducible transcript 3 Homo sapiens 126-130 10674903-1 2000 A regimen which incorporates cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) is the standard treatment for patients with non-Hodgkin"s lymphoma (NHL), but it has not been effective in patients with aggressive NHL who are at high risk. Cyclophosphamide 29-45 DNA damage inducible transcript 3 Homo sapiens 90-94 11269797-6 2001 Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) therapy was given, and the patient became asymptomatic with normal blood tests and was thought to be in remission. Cyclophosphamide 0-16 DNA damage inducible transcript 3 Homo sapiens 60-64 11230885-1 2001 BACKGROUND: A limited number cycles of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy followed by involved field radiotherapy is the treatment of choice for Ann Arbor stage I intermediate or high grade non-Hodgkin"s lymphomas (NHL). Cyclophosphamide 39-55 DNA damage inducible transcript 3 Homo sapiens 98-102 11002232-2 2000 The Medical Research Council therefore conducted the current randomized trial to assess the impact on survival of postradiotherapy chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in nonimmunocompromised adult patients with pathologically proven PCL. Cyclophosphamide 149-165 DNA damage inducible transcript 3 Homo sapiens 209-213 9711921-0 1998 A phase I trial of standard and cyclophosphamide dose-escalated CHOP with granulocyte colony stimulating factor in elderly patients with non-Hodgkin"s lymphoma. Cyclophosphamide 32-48 DNA damage inducible transcript 3 Homo sapiens 64-68 10463009-13 1999 CHOP (cyclophosphamide 650 mg/m2 day 1, vincristine 1.4 mg/m2 day 1, doxorubicin--45 mg/m2 day 1 and prednisone 100 mg/m2 day 1-5) was the most common chemotherapy regimen used. Cyclophosphamide 6-22 DNA damage inducible transcript 3 Homo sapiens 0-4 9827356-4 1998 CHOP protocol is containing both proved carcinogenic cyclophosphamide and highly mutagenic doxorubicyn. Cyclophosphamide 53-69 DNA damage inducible transcript 3 Homo sapiens 0-4 9711921-9 1998 Six of 11 patients (55%) given CHOP with cyclophosphamide 900 mg/m2 (CHOP-900) completed treatment. Cyclophosphamide 41-57 DNA damage inducible transcript 3 Homo sapiens 31-35 9711921-9 1998 Six of 11 patients (55%) given CHOP with cyclophosphamide 900 mg/m2 (CHOP-900) completed treatment. Cyclophosphamide 41-57 DNA damage inducible transcript 3 Homo sapiens 69-73 9711921-12 1998 The received dose intensities of cyclophosphamide relative to standard CHOP measured over the actual time on therapy were 96% with standard CHOP and 115% with CHOP-900. Cyclophosphamide 33-49 DNA damage inducible transcript 3 Homo sapiens 140-144 9711921-12 1998 The received dose intensities of cyclophosphamide relative to standard CHOP measured over the actual time on therapy were 96% with standard CHOP and 115% with CHOP-900. Cyclophosphamide 33-49 DNA damage inducible transcript 3 Homo sapiens 140-144 9711921-1 1998 The purpose of this study was to assess the safety and feasibility of using standard and escalated doses of cyclophosphamide with doxorubicin, vincristine and prednisone (CHOP) plus granulocyte colony stimulating factor (G-CSF) to treat elderly patients who have advanced stage intermediate grade lymphoma. Cyclophosphamide 108-124 DNA damage inducible transcript 3 Homo sapiens 171-175 9667250-1 1998 PURPOSE: Standard cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy repeated at 3-week intervals is difficult to deliver in elderly patients with non-Hodgkin"s lymphoma (NHL). Cyclophosphamide 18-34 DNA damage inducible transcript 3 Homo sapiens 78-82 9519935-7 1998 We describe a patient with non-Hodgkin"s lymphoma treated with conventional cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy and high-dose steroids who developed a rapidly progressive fatal leukoencephalopathy. Cyclophosphamide 76-92 DNA damage inducible transcript 3 Homo sapiens 136-140 9649147-3 1998 CHOP therapy (cyclophosphamide, doxorubicin, vincristine and prednisolone) only slightly induces pulmonary toxicity. Cyclophosphamide 14-30 DNA damage inducible transcript 3 Homo sapiens 0-4 9752311-1 1998 The CHOP regimen (cyclophosphamide vincristine, adriamycin, prednisone) is considered since twenty years as the standard treatment of disseminated aggressive non-Hodgkin"s lymphomas and cures approximately 30% of patients. Cyclophosphamide 18-34 DNA damage inducible transcript 3 Homo sapiens 4-8 10173030-3 1997 One such treatment that is considered to have a low potential for inducing fever and neutropenia is the CHOP regimen (cyclophosphamide, doxorubicin, vincristine and prednisone) for non-Hodgkin"s lymphoma. Cyclophosphamide 118-134 DNA damage inducible transcript 3 Homo sapiens 104-108 9409065-1 1997 Cyclophosphamide, doxorubicin, vincristine (Oncovin), and prednisolone (CHOP) has for many years been the standard chemotherapeutic regimen for patients with aggressive non-Hodgkin"s lymphoma. Cyclophosphamide 0-16 DNA damage inducible transcript 3 Homo sapiens 72-76 9179527-4 1997 Conventional chemotherapy with CHOP (a chemotherapeutic regimen consisting of a combination of cyclophosphamide, doxorubicin, vincristine and prednisone) or other equivalent third-generation regimens may be considered the standard treatment for the good prognosis group. Cyclophosphamide 95-111 DNA damage inducible transcript 3 Homo sapiens 31-35 9491847-0 1997 Results of treatment with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) for non-Hodgkin"s aggressive lymphoma analyzed according to the International Prognostic Index. Cyclophosphamide 26-42 DNA damage inducible transcript 3 Homo sapiens 85-89 9115450-3 1997 Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy is well tolerated in patients who have a good performance status and who have aggressive histology lymphoma, but briefer 8-week regimens appear to offer similar benefits more quickly. Cyclophosphamide 0-16 DNA damage inducible transcript 3 Homo sapiens 60-64 8978792-3 1996 The efficacy of dose intensification of CPA in CHOP regimen for patients with aggressive lymphoma is being investigated in some clinical trials. Cyclophosphamide 40-43 DNA damage inducible transcript 3 Homo sapiens 47-51 8629263-5 1996 The CHOP-regime, consisting of doxorubicin, cyclophosphamide, oncovin and prednisolon, is the standard therapy that should be given outside of clinical trials. Cyclophosphamide 44-60 DNA damage inducible transcript 3 Homo sapiens 4-8 8636770-9 1996 Treatment with cyclophosphamide, doxorubicin vincristine, and prednisone (CHOP) or cyclophosphomide, vincristine, and prednisone (COP) resulted in a complete remission in 14 of 15 cases. Cyclophosphamide 15-31 DNA damage inducible transcript 3 Homo sapiens 74-78 8688344-1 1996 A combination of cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) has been a standard therapy for histologically aggressive non-Hodgkin"s lymphomas for over 20 years, but several newer regimens, referred to as second or third generation, have been reported to give improved results in single-centre studies. Cyclophosphamide 17-33 DNA damage inducible transcript 3 Homo sapiens 78-82 8652232-5 1995 In high-grade lymphomas combination chemotherapy with cyclophosphamide, hydroxydaunorubin, vincristine and prednisone (CHOP) represents the treatment of first choice, and may be restricted to 3-4 cycles in patients with limited stages of the disease when followed by involved field radiotherapy. Cyclophosphamide 54-70 DNA damage inducible transcript 3 Homo sapiens 119-123 8038494-13 1993 In a previous randomized trial, the French Co-operative Group on CLL showed a beneficial role for low-dose adriamycin given with cyclophosphamide, vincristine and prednisone (mini-CHOP) in patients with stage C disease. Cyclophosphamide 129-145 DNA damage inducible transcript 3 Homo sapiens 180-184 8523055-3 1995 The study was designed to determine the maximum-tolerated dosages (MTD) of cyclophosphamide and doxorubicin that could be used in a high-dose cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen with granulocyte colony-stimulating factor (G-CSF) support and to assess preliminarily the efficacy of the regimen. Cyclophosphamide 75-91 DNA damage inducible transcript 3 Homo sapiens 202-206 7521788-8 1994 The safety of increasing the dose of cyclophosphamide during biweekly CHOP then was tested. Cyclophosphamide 37-53 DNA damage inducible transcript 3 Homo sapiens 70-74 7521788-18 1994 CONCLUSIONS: The dose of cyclophosphamide in biweekly CHOP can be increased up to 1500 mg/m2 with no increase in the incidence of treatment-related early mortalities without any organ damage in younger patients. Cyclophosphamide 25-41 DNA damage inducible transcript 3 Homo sapiens 54-58 7521788-19 1994 The efficacy of this dose intensification of CHOP currently is being investigated in a multicenter prospective randomized trial using three different dose levels of cyclophosphamide. Cyclophosphamide 165-181 DNA damage inducible transcript 3 Homo sapiens 45-49 8285167-9 1993 After systemic chemotherapy of cyclophosphamide, adriamycin, vincristine, prednisone (CHOP) regimen, renal function improved and the tumor of stomach reduced, but his respiratory condition rapidly worsened, and he died about 1 month after chemotherapy. Cyclophosphamide 31-47 DNA damage inducible transcript 3 Homo sapiens 86-90 8369658-11 1993 Our successful treatment is radiation therapy combined with six courses of CHOP chemotherapy (cyclophosphamide, adriamycin, vincristine, prednisolone). Cyclophosphamide 94-110 DNA damage inducible transcript 3 Homo sapiens 75-79 7680764-1 1993 BACKGROUND: CHOP is a first-generation, combination-chemotherapy regimen consisting of cyclophosphamide, doxorubicin, vincristine, and prednisone that has cured approximately 30 percent of patients with advanced stages of intermediate-grade or high-grade non-Hodgkin"s lymphoma in national cooperative-group trials. Cyclophosphamide 87-103 DNA damage inducible transcript 3 Homo sapiens 12-16 2317752-4 1990 Continuous CHOP protocol consists of initial 8 weeks of intensive chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone, followed by local/cranial radiotherapy and maintenance therapy. Cyclophosphamide 84-100 DNA damage inducible transcript 3 Homo sapiens 11-15 8469201-6 1993 TREATMENT AND OUTCOME: After initial response to CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisolone), she relapsed and died with central nervous system involvement eight months after the initial diagnosis. Cyclophosphamide 68-84 DNA damage inducible transcript 3 Homo sapiens 49-53 2246824-6 1990 After chemotherapy using adriamycin, cyclophosphamide, vincristine, and prednisolone (CHOP), lymphadenopathy and splenomegaly reduced and lymphoid blasts disappeared from the blood and bone marrow. Cyclophosphamide 37-53 DNA damage inducible transcript 3 Homo sapiens 86-90 8426200-8 1993 CONCLUSION: Pelvic XRT and cumulative cyclophosphamide dosages greater than 9.5 g/m2 are associated with a high risk of permanent sterility in lymphoma patients treated with the CHOP-Bleo regimen. Cyclophosphamide 38-54 DNA damage inducible transcript 3 Homo sapiens 178-182 1383819-8 1992 The median normalized dose intensity for both cyclophosphamide and doxorubicin was found to be greater in the patients treated with CHOP than in those treated with m-BACOD. Cyclophosphamide 46-62 DNA damage inducible transcript 3 Homo sapiens 132-136 1630019-6 1992 The patient was treated with the CHOP regimen (doxorubicin, cyclophosphamide, vincristine and prednisolone), which achieved complete remission. Cyclophosphamide 60-76 DNA damage inducible transcript 3 Homo sapiens 33-37 34843406-2 2022 Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) therapy is widely used as first-line treatment of PTCL; however, it has limited efficacy. Cyclophosphamide 0-16 DNA damage inducible transcript 3 Homo sapiens 60-64 33591324-1 2021 Rituximab plus cyclophosphamide-doxorubicin-vincristine-prednisone (R-CHOP) is the standard of care for untreated diffuse large B-cell lymphoma (DLBCL). Cyclophosphamide 15-31 DNA damage inducible transcript 3 Homo sapiens 70-74 33233444-4 2020 CPA, an integral component of CHOP, is a prodrug that requires CYP2B6-mediated bioactivation to 4-hydroxy-CPA (4-OH-CPA). Cyclophosphamide 0-3 DNA damage inducible transcript 3 Homo sapiens 30-34 30091025-1 2018 The standard treatment for diffuse large B cell lymphoma (DLBCL) is rituximab with CHOP (cyclophosphamide, doxorubicin, vincristine (VCR), and prednisone). Cyclophosphamide 89-105 DNA damage inducible transcript 3 Homo sapiens 83-87 33944646-5 2021 The main focus of this study was on newly diagnosed patients receiving cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) versus other chemotherapy. Cyclophosphamide 71-87 DNA damage inducible transcript 3 Homo sapiens 131-135 34745610-0 2021 Intratumoral T-cell receptor repertoire is predictive of interim PET scan results in patients with diffuse large B-cell lymphoma treated with rituximab/cyclophosphamide/doxorubicin/prednisolone/vincristine (R-CHOP) chemoimmunotherapy. Cyclophosphamide 152-168 DNA damage inducible transcript 3 Homo sapiens 209-213 34990525-1 2021 Purpose: Febrile neutropenia (FN) can cause suboptimal treatment and treatment-related mortality (TRM) in diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP). Cyclophosphamide 177-193 DNA damage inducible transcript 3 Homo sapiens 241-245 34732441-6 2021 Moreover, high risk, defined as co-expression of BTK and either or both BCL2/MYC, independently predicted shorter progression-free survival in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) (all R-CHOP-treated patients: hazard ratio=2.565, p=0.044; R-CHOP-treated non-GCB subgroup: HR=3.833, p=0.019). Cyclophosphamide 180-196 DNA damage inducible transcript 3 Homo sapiens 241-245 34565287-0 2021 Silencing aurora-kinase-A (AURKA) reinforced the sensitivity of diffuse large B-cell lymphoma cells to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) via suppressing beta-Catenin and RAS-extracellular signal-regulated protein kinase (ERK1/2) pathway. Cyclophosphamide 103-119 DNA damage inducible transcript 3 Homo sapiens 163-167 34565287-1 2021 The therapeutic effects of standard cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) therapy for prevalent lymphoma diffuse large B-cell lymphoma (DLBC, DLBCL) still require improvement. Cyclophosphamide 36-52 DNA damage inducible transcript 3 Homo sapiens 95-99 34797531-1 2022 Patients with high-risk diffuse large B-cell lymphoma (DLBCL) have poor outcomes following first-line cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab (R-CHOP). Cyclophosphamide 102-118 DNA damage inducible transcript 3 Homo sapiens 175-179 34745610-1 2021 Objectives: A diverse intratumoral T-cell receptor (TCR) repertoire is associated with improved survival in diffuse large B-cell lymphoma (DLBCL) treated with rituximab/cyclophosphamide/doxorubicin/prednisolone/vincristine (R-CHOP) chemoimmunotherapy. Cyclophosphamide 169-185 DNA damage inducible transcript 3 Homo sapiens 226-230 34254266-1 2022 PURPOSE: Comprehensive geriatric assessment (CGA) has been used to help identify elderly patients with diffuse large B-cell lymphoma (DLBCL) who were suitable for rituximab combined with CHOP therapy (cyclophosphamide, Adriamycin, vincristine, and prednisolone), but there are few reports of CGA for elderly patients with DLBCL who received R-mini-CHOP. Cyclophosphamide 201-217 DNA damage inducible transcript 3 Homo sapiens 187-191 34895738-7 2021 CASE SUMMARY: An 81-year-old female patient received her first cycle of R-CHOP (rituximab, cyclophosphamide, vincristine, and prednisolone) treatment after being diagnosed with high- grade B-cell lymphoma. Cyclophosphamide 91-107 DNA damage inducible transcript 3 Homo sapiens 74-78 34765356-4 2021 We report a case of a 65-year-old man who presented with acutely worsening dyspnoea and stridor following his fifth cycle of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) chemotherapy for hematological malignancy. Cyclophosphamide 136-152 DNA damage inducible transcript 3 Homo sapiens 200-204 34586105-2 2021 The current first-line regimen for the treatment of DLBCL is R-CHOP, which is the combination of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone. Cyclophosphamide 108-124 DNA damage inducible transcript 3 Homo sapiens 63-67 35468783-1 2022 BACKGROUND: Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) has been used to treat patients with diffuse large B-cell lymphoma (DLBCL) under National Health Insurance (NHI) scheme in Indonesia. Cyclophosphamide 27-43 DNA damage inducible transcript 3 Homo sapiens 89-93 34124276-1 2021 The majority of diffuse large B-cell lymphoma (DLBCL) patients develop relapsed or refractory disease after standard ruxolitinib, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy, which is partly related to a dysregulated tumor immune microenvironment. Cyclophosphamide 130-146 DNA damage inducible transcript 3 Homo sapiens 192-196 35573753-3 2022 We report a case of a 67-year-old woman with a story of non-Hodgkin lymphoma treated with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone), who got a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection while being totally depleted of B cells. Cyclophosphamide 113-129 DNA damage inducible transcript 3 Homo sapiens 92-96 35096395-6 2022 She received six cycles R-CHOP chemotherapy (rituximab, cyclophosphamide, epirubicin, vincristine, and prednisone) with complete resolution of the mass. Cyclophosphamide 56-72 DNA damage inducible transcript 3 Homo sapiens 26-30 35297262-13 2022 The patient received treatment with mini-CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisolone) plus rituximab with partial response after the third cycle. Cyclophosphamide 60-76 DNA damage inducible transcript 3 Homo sapiens 41-45 35451406-1 2022 ABSTRACT: Maintaining relative dose intensity (RDI) of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) improves the prognosis of patients with diffuse large B-cell lymphoma (DLBCL). Cyclophosphamide 66-82 DNA damage inducible transcript 3 Homo sapiens 128-132 3167803-6 1988 Employing CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone) and consolidation radiation therapy in most cases, 80% achieved a complete remission and 59% survive failure-free at 5 years by actuarial calculation. Cyclophosphamide 29-45 DNA damage inducible transcript 3 Homo sapiens 10-14 35044836-1 2022 PURPOSE: Rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) represents the standard of care for first-line treatment of diffuse large B-cell lymphoma (DLBCL). Cyclophosphamide 24-40 DNA damage inducible transcript 3 Homo sapiens 88-92 3203011-0 1988 Treatment of diffuse histiocytic and diffuse mixed non-Hodgkin lymphomas with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP). Cyclophosphamide 78-94 DNA damage inducible transcript 3 Homo sapiens 137-141 6090736-6 1984 Complete remission was obtained by CHOP therapy (consisting of cyclophosphamide, adriamycin, vincristine, and prednisolone) combined with cervical irradiation. Cyclophosphamide 63-79 DNA damage inducible transcript 3 Homo sapiens 35-39 3840280-2 1985 We have reported a case of diffuse, poorly differentiated lymphocytic lymphoma, stage IIIa, in a patient whose disease went into remission after she received six courses of CHOP therapy (cyclophosphamide, doxorubicin, vincristine, and prednisolone). Cyclophosphamide 187-203 DNA damage inducible transcript 3 Homo sapiens 173-177 3581030-0 1987 Cyclophosphamide, vincristine, adriamycin, and prednisone (CHOP) with and without intermediate dose methotrexate for the treatment of non-Hodgkin"s lymphomas of diffuse histology. Cyclophosphamide 0-16 DNA damage inducible transcript 3 Homo sapiens 59-63 3754070-2 1986 We describe a case of a 68-year-old man with an immunoblastic primary cerebral lymphoma first treated with surgery and radiotherapy and subsequently with chemotherapy consisting of cyclophosphamide, adriamycin, vincristine and prednisone (CHOP). Cyclophosphamide 181-197 DNA damage inducible transcript 3 Homo sapiens 239-243 6688200-0 1983 Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in patients with advanced Hodgkin"s disease: a Southwest Oncology Group Phase II Study. Cyclophosphamide 0-16 DNA damage inducible transcript 3 Homo sapiens 60-64 6697295-4 1984 A few hours after initiation of chemotherapy with cyclophosphamide, Adriamycin (doxorubicin), vincristine, and prednisolone (CHOP regimen), the patient developed an acute ascending paralysis. Cyclophosphamide 50-66 DNA damage inducible transcript 3 Homo sapiens 125-129 6347997-1 1983 The combination of cyclophosphamide, adriamycin, vincristine, and prednisone (CHOP) alternating with total body irradiation (TBI) has been shown earlier to be effective therapy in patients with malignant lymphoma who have received prior chemotherapy and/or radiation therapy. Cyclophosphamide 19-35 DNA damage inducible transcript 3 Homo sapiens 78-82 6347997-4 1983 CHOP was given in the following manner: cyclophosphamide 400 mg/M2 IV day 1, adriamycin 40 mg/M2 IV day 1, vincristine 2 mg IV day 1, and Prednisone 100 mg po daily X 5. Cyclophosphamide 40-56 DNA damage inducible transcript 3 Homo sapiens 0-4 7233568-0 1980 Combination chemotherapy with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP) for non-Hodgkin"s lymphomas with unfavorable histology: preliminary results. Cyclophosphamide 30-46 DNA damage inducible transcript 3 Homo sapiens 88-92 6191677-0 1983 [Cyclophosphamide, adriamycin, vincristine, bleomycin and prednisolone (CHOP-Bleo) combination chemotherapy for advanced non-Hodgkin"s lymphoma]. Cyclophosphamide 1-17 DNA damage inducible transcript 3 Homo sapiens 72-76 6950800-5 1982 Combination chemotherapy with cyclophosphamide, Doxorubicin, vincristine, and prednisone (CHOP) has produced impressive clinical responses in patients with PL. Cyclophosphamide 30-46 DNA damage inducible transcript 3 Homo sapiens 90-94 33734921-1 2021 BACKGROUND: Treatment with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is standard of care first line treatment for diffuse large B-cell lymphoma (DLBCL), though outcomes remain suboptimal. Cyclophosphamide 38-54 DNA damage inducible transcript 3 Homo sapiens 100-104 364284-1 1978 The results of a chemotherapy regimen utilizing adriamycin in combination with vincristine, prednisone plus or minus cyclophosphamide (CHOP-HOP) for the treatment of non-Hodgkin lymphoma are compared to those of a non-adriamycin containing combination (COP). Cyclophosphamide 117-133 DNA damage inducible transcript 3 Homo sapiens 135-139 33688781-1 2021 Peripheral T-cell lymphoma (PTCL) is a group of aggressive lymphomas commonly treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). Cyclophosphamide 91-107 DNA damage inducible transcript 3 Homo sapiens 151-155 33483276-1 2021 BACKGROUND: The R-CHOP regimen (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) is the standard therapy for patients with diffuse large B-cell lymphoma (DLBCL). Cyclophosphamide 43-59 DNA damage inducible transcript 3 Homo sapiens 18-22 33592897-8 2021 INTERVENTIONS: The patient was first treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen. Cyclophosphamide 54-70 DNA damage inducible transcript 3 Homo sapiens 114-118 33625586-1 2021 BACKGROUND: A combination of rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is the standard first-line therapy for diffuse large B cell lymphoma (DLBCL), the most common aggressive lymphoma in adults. Cyclophosphamide 44-60 DNA damage inducible transcript 3 Homo sapiens 106-110 33573703-1 2021 BACKGROUND: Although R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) remains the standard chemotherapy regimen for diffuse large B cell lymphoma (DLBCL) patients, not all patients are responsive to the scheme, and there is no effective method to predict treatment response. Cyclophosphamide 40-56 DNA damage inducible transcript 3 Homo sapiens 23-27 33317571-1 2020 As a widely recognized standard regimen, R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) is able to cure two-thirds patients with diffuse large B cell lymphoma (DLBCL), and the remaining patients suffer from refractory or relapsed disease due to resistance to R-CHOP and fare poorly. Cyclophosphamide 64-80 DNA damage inducible transcript 3 Homo sapiens 43-47 33436910-2 2021 This study aimed to compare the area under the plasma concentration-time curves (AUCs) of vincristine (VCR), doxorubicin (DXR), and cyclophosphamide (CPA) between (R-)CHOP and (R-)miniCHOP regimens. Cyclophosphamide 132-148 DNA damage inducible transcript 3 Homo sapiens 167-171 33436910-5 2021 The median AUCs of DXR and CPA were significantly smaller in the (R-)miniCHOP group than in the (R-)CHOP group (168.7 vs. 257.9 ng h/mL, P = 0.003, and 219.9 vs. 301.7 microg h/mL, P = 0.020, respectively). Cyclophosphamide 27-30 DNA damage inducible transcript 3 Homo sapiens 73-77 33436910-7 2021 It is possible that the AUCs of VCR, DXR, and CPA in patients aged 80 years and older receiving (R-)miniCHOP therapy may be lower than those in patients 65-79 years old receiving (R-)CHOP therapy. Cyclophosphamide 46-49 DNA damage inducible transcript 3 Homo sapiens 104-108 33230132-2 2020 The standard treatment is the CHOP chemotherapy protocols that include cyclophosphamide, doxorubicin, vincristine and prednisone, where the majority of dogs achieve complete/partial response; however, it is very important to predict non-responsive cases to improve treatment and to develop new targeted therapies. Cyclophosphamide 71-87 DNA damage inducible transcript 3 Homo sapiens 30-34 33269174-3 2020 Recent studies have demonstrated a potential benefit with combination of dose-adjusted rituximab, etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-REPOCH) in comparison to standard combination chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in ABC DLBCL patients. Cyclophosphamide 134-150 DNA damage inducible transcript 3 Homo sapiens 296-300 32994268-5 2020 PBL is an extremely aggressive lymphoma and is usually treated using a CHOP-like regimen (cyclophosphamide, doxorubicin, vincristine and prednisone/dexamethasone), but with poor outcome. Cyclophosphamide 90-106 DNA damage inducible transcript 3 Homo sapiens 71-75 33116822-6 2020 Subsequently, the patient was treated by six cycles of CHOP (cyclophosphamide + doxorubicin + vincristine + hydroprednisone) regimens. Cyclophosphamide 61-77 DNA damage inducible transcript 3 Homo sapiens 55-59 32042095-3 2020 In current study, we aimed to explore the association between gene networks and overall survival (OS) of DLBCL patients treated with CHOP-based chemotherapy (cyclophosphamide combination with doxorubicin, vincristine and prednisone). Cyclophosphamide 158-174 DNA damage inducible transcript 3 Homo sapiens 133-137 32623836-6 2020 ABT-737 combined with a low dose of cyclophosphamide, a major component of the conventional CHOP chemotherapy regimen for BL patients, reduced tumor growth during treatment but failed to improve the overall survival of BL xenograft mice. Cyclophosphamide 36-52 DNA damage inducible transcript 3 Homo sapiens 92-96 32915975-2 2020 Exposure to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) is likely to increase the risk of fracture, but evidence is lacking to define fracture incidence in this group. Cyclophosphamide 31-47 DNA damage inducible transcript 3 Homo sapiens 14-18 32417940-2 2020 Progression or relapse of FL within 2 years (so-called POD24) after diagnosis is associated with a poor outcome for patients treated with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone) in clinical trials. Cyclophosphamide 161-177 DNA damage inducible transcript 3 Homo sapiens 140-144 33093947-3 2020 R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) is accepted as the international standard first-line regimen, but improvement in first line treatment is needed. Cyclophosphamide 19-35 DNA damage inducible transcript 3 Homo sapiens 2-6 32648457-1 2020 BACKGROUND: The CHOP regimen comprising cyclophosphamide, doxorubicin, vincristine, and prednisone is a basic chemotherapeutic regimen for diffuse large B cell lymphoma (DLBCL). Cyclophosphamide 40-56 DNA damage inducible transcript 3 Homo sapiens 16-20 31185769-2 2019 Among 65% of patients receiving treatment after diagnosis, R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) was the most common frontline therapy, increasing with more recent treatment year: 51% (2001-2003) vs. 69% (2010-2014). Cyclophosphamide 78-94 DNA damage inducible transcript 3 Homo sapiens 61-65 32187361-11 2020 The identification of both good and poor risk subtypes in patients treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) clearly show the clinical value of the approach, confirming the need for a consensus classification. Cyclophosphamide 99-115 DNA damage inducible transcript 3 Homo sapiens 82-86 31902733-4 2020 Our findings demonstrate good outcomes following induction treatment with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), suggesting that these cases can be treated as DLBCL rather than primary central nervous system lymphoma, obviating the need for more aggressive and toxic approaches. Cyclophosphamide 93-109 DNA damage inducible transcript 3 Homo sapiens 76-80 32250167-1 2020 While combination of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) cures most patients with diffuse large B-cell lymphoma (DLBCL), those with high-risk international prognostic index disease have inferior survival. Cyclophosphamide 32-48 DNA damage inducible transcript 3 Homo sapiens 93-97 32349779-1 2020 BACKGROUND: Cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP)/CHOP-like chemotherapy is widely used in peripheral T cell lymphoma (PTCL). Cyclophosphamide 12-28 DNA damage inducible transcript 3 Homo sapiens 74-78 32112707-5 2020 In a small sample size, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (EPOCH-R) achieved better outcomes than a regimen of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Cyclophosphamide 60-76 DNA damage inducible transcript 3 Homo sapiens 231-235 32028388-7 2020 INTERVENTIONS: The patient was successfully treated by Poly-chemotherapy with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vindesine and prednisolone). Cyclophosphamide 97-113 DNA damage inducible transcript 3 Homo sapiens 80-84 31868632-1 2019 BACKGROUND: Six cycles of R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) are the standard treatment for aggressive B-cell non-Hodgkin lymphoma. Cyclophosphamide 49-65 DNA damage inducible transcript 3 Homo sapiens 28-32 30101679-1 2019 OBJECTIVES: Chemoimmunotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with rituximab (R-CHOP) is currently the first-line therapy for diffuse large B-cell lymphoma (DLBCL). Cyclophosphamide 36-52 DNA damage inducible transcript 3 Homo sapiens 124-128 31852157-11 2019 INTERVENTIONS: The current first-line treatment for diffuse large B-cell lymphoma is the cyclophosphamide, adriamycin, vincristine, prednisone (CHOP) protocol. Cyclophosphamide 89-105 DNA damage inducible transcript 3 Homo sapiens 144-148 31516154-4 2019 He was managed by the oncologist with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) regimen which alleviated his symptoms considerably after completion of three cycles and was under follow-up. Cyclophosphamide 57-73 DNA damage inducible transcript 3 Homo sapiens 40-44 31832222-1 2019 Background: Cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) regimen includes a high dose of prednisolone (100 mg/body), which exhibits an anticancer and antiemetic effect. Cyclophosphamide 12-28 DNA damage inducible transcript 3 Homo sapiens 74-78 31314918-1 2019 OBJECTIVES: R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) is the standard therapy for patients with previously untreated diffuse large B-cell lymphomas (DLBCL). Cyclophosphamide 31-47 DNA damage inducible transcript 3 Homo sapiens 14-18 31222719-1 2019 Central nervous system (CNS) relapse following R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) occurs in 2-5% of patents with diffuse large B-cell lymphoma (DLBCL). Cyclophosphamide 66-82 DNA damage inducible transcript 3 Homo sapiens 49-53 31118164-2 2019 The use of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) could overcome these difficulties, but blood-brain barrier (BBB) penetration of related drugs is poor. Cyclophosphamide 30-46 DNA damage inducible transcript 3 Homo sapiens 13-17 30689002-0 2019 Cyclophosphamide dose adjustment based on body weight and albuminemia in elderly patients treated with R-mini-CHOP. Cyclophosphamide 0-16 DNA damage inducible transcript 3 Homo sapiens 110-114 30307363-5 2019 She was treated with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy which was complicated by prolonged pancytopenia, without response. Cyclophosphamide 21-37 DNA damage inducible transcript 3 Homo sapiens 80-84 30788202-10 2018 The patient was treated with six courses of CHOP-R (cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab). Cyclophosphamide 52-68 DNA damage inducible transcript 3 Homo sapiens 44-48 30101910-1 2018 Objective Although R-CHOP (rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisone) is a standard therapy for diffuse large B-cell lymphoma (DLBCL), the optimal dose for elderly patients remains unclear. Cyclophosphamide 38-54 DNA damage inducible transcript 3 Homo sapiens 21-25 31597843-2 2019 R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) remains the standard treatment for diffuse large B-cell lymphoma (DLBCL) in line with the prior 2013 guidelines. Cyclophosphamide 19-35 DNA damage inducible transcript 3 Homo sapiens 2-6 30431571-4 2018 INTERVENTIONS AND OUTCOMES: Fortunately, the patient"s skin lesions subsided gradually after 3 cycles of cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) regimen. Cyclophosphamide 105-121 DNA damage inducible transcript 3 Homo sapiens 167-171 30172345-1 2018 BACKGROUND: Immunochemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is a standard front-line treatment for follicular lymphoma. Cyclophosphamide 47-63 DNA damage inducible transcript 3 Homo sapiens 109-113 30340554-1 2018 BACKGROUND: Rituximab plus combination chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is broadly accepted as standard for the treatment of diffuse large B-cell lymphoma (DLBCL). Cyclophosphamide 57-73 DNA damage inducible transcript 3 Homo sapiens 119-123 30190020-4 2018 Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is a highly effective but potentially neurotoxic regimen. Cyclophosphamide 11-27 DNA damage inducible transcript 3 Homo sapiens 73-77 30313105-6 2018 The patient was treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP).Neurological symptoms improved with R-CHOP. Cyclophosphamide 40-56 DNA damage inducible transcript 3 Homo sapiens 146-150 29410666-2 2018 However, this model involves animals with high tumor burden, whereas in the clinics B-NHL patients are usually treated with chemotherapy (CHOP: cyclophosphamide, doxorubicin, vincristine, and prednisone) as first-line therapy prior to immunotherapy. Cyclophosphamide 144-160 DNA damage inducible transcript 3 Homo sapiens 138-142 29963517-2 2018 The R-CHOP therapy [rituximab (R), cyclophosphamide, hydroxy-doxorubicin, vincristine, and prednisone] is a popular and recommended regimen for primary therapy, prescribed by several treatment guidelines for WM. Cyclophosphamide 35-51 DNA damage inducible transcript 3 Homo sapiens 6-10 29467881-1 2018 Treatment with rituximab plus a regimen of cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) for patients with diffuse large B-cell lymphoma (DLBCL) has proven efficacy in clinical trials. Cyclophosphamide 43-59 DNA damage inducible transcript 3 Homo sapiens 104-108 28791403-10 2017 Among DLBCL cases, the TP53 mutations shortened both OS and PFS of patients treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) and decreased both OS and PFS of patients with secondary DLBCL disease. Cyclophosphamide 108-124 DNA damage inducible transcript 3 Homo sapiens 91-95 29737107-7 2018 R-CHOP (rituximab,cyclophosphamide,epirubicin,vindesine,prednisone) or CHOP regimen chemotherapy significantly improved the survival of the patients (P=0.000 2). Cyclophosphamide 18-34 DNA damage inducible transcript 3 Homo sapiens 2-6 29333403-1 2017 Background: While cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) is the most commonly used chemotherapeutic regimen for patients with peripheral T-cell lymphomas (PTCLs), elderly patients are more vulnerable to associated toxicities. Cyclophosphamide 18-34 DNA damage inducible transcript 3 Homo sapiens 80-84 29296861-2 2017 Despite producing somewhat less-than-satisfactory results, the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) remains the de facto standard in PTCL treatment. Cyclophosphamide 78-94 DNA damage inducible transcript 3 Homo sapiens 138-142 26449182-1 2017 The CHOP regimen consisting of cyclophosphamide, doxorubicin (DOX), vincristine and prednisolone has been the most used regimen for peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS). Cyclophosphamide 31-47 DNA damage inducible transcript 3 Homo sapiens 4-8 28522441-2 2017 We hypothesized that rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) could decrease rates of relapse and transformation. Cyclophosphamide 36-52 DNA damage inducible transcript 3 Homo sapiens 98-102 28725161-1 2017 BACKGROUND: Rituximab combined with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) is used as standard frontline regimen for diffuse large B-cell lymphoma (DLBCL). Cyclophosphamide 36-52 DNA damage inducible transcript 3 Homo sapiens 95-99 28445949-6 2017 These cells survived longer following treatment with a combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP). Cyclophosphamide 70-86 DNA damage inducible transcript 3 Homo sapiens 129-133 27382104-1 2016 PURPOSE: Utility of combined-modality therapy for patients with limited-stage diffuse large B-cell lymphoma (DLBCL) was shown in the Southwest Oncology Group (SWOG) S8736 study, where three cycles of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) plus radiotherapy (CHOP3RT) improved 5-year progression-free (PFS) and overall survival (OS) compared with eight cycles of CHOP (CHOP8). Cyclophosphamide 206-222 DNA damage inducible transcript 3 Homo sapiens 200-204 28559645-7 2017 TREATMENT AND OUTCOME: The patient had a good initial response to a CHOP scheme (cyclophosphamide, doxorubicin, vincristine and prednisone) with filgrastim. Cyclophosphamide 81-97 DNA damage inducible transcript 3 Homo sapiens 68-72 27928587-1 2017 Cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP)/CHOP-like chemotherapy has been mostly applied to patients with untreated peripheral T cell lymphoma (PTCL). Cyclophosphamide 0-16 DNA damage inducible transcript 3 Homo sapiens 62-66 27283030-4 2017 The patient was diagnosed with PEL-LL and treated with six cycles of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP), which resulted in a complete remission. Cyclophosphamide 84-100 DNA damage inducible transcript 3 Homo sapiens 148-152 28978846-6 2017 From recent prospective trials, conventional R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) regimen, which is the current standard regimen for DLBCL, has been acknowledged as a well-established regimen for DLBCL. Cyclophosphamide 64-80 DNA damage inducible transcript 3 Homo sapiens 47-51 28030899-8 2016 In univariate analysis, the rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) regimen resulted in a better PFS than the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen (88.9% vs. 50.0%; p = 0.053). Cyclophosphamide 39-55 DNA damage inducible transcript 3 Homo sapiens 209-213 27129176-1 2016 Cyclophosphamide, doxorubicin, vincristine, and prednisolone plus rituximab (R-CHOP) is the standard treatment for patients with diffuse large B cell lymphoma (DLBCL). Cyclophosphamide 0-16 DNA damage inducible transcript 3 Homo sapiens 79-83 27462230-10 2016 Two years after, the patient suffered a relapse and underwent 6 cycles of CHOP-R (cyclophosphamide, hydroxydaunomycin, oncovin, prednisone, and rituximab), achieving partial remission. Cyclophosphamide 82-98 DNA damage inducible transcript 3 Homo sapiens 74-78 26986862-5 2016 We present a patient with T/myeloid mixed-phenotype acute leukemia secondary to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone R-CHOP chemotherapy for primary cutaneous diffuse large B-cell lymphoma. Cyclophosphamide 91-107 DNA damage inducible transcript 3 Homo sapiens 152-156 26990931-1 2016 BACKGROUND: Chemoimmunotherapy containing rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) is the standard treatment for diffuse large B-cell lymphoma (DLBCL). Cyclophosphamide 53-69 DNA damage inducible transcript 3 Homo sapiens 117-121 26834485-7 2016 CONCLUSION: It is generally believed that the regimen consisting of cyclophosphamide, hydroxydaunorubicin (doxorubicin), vincristine, and prednisolone (CHOP) is also applicable to ALCL. Cyclophosphamide 68-84 DNA damage inducible transcript 3 Homo sapiens 152-156 24675549-1 2016 This article describes the first reported case of dramatic lymphocytosis flare after initiation of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) therapy for an indolent lymphoma. Cyclophosphamide 118-134 DNA damage inducible transcript 3 Homo sapiens 101-105 27034868-10 2016 The patient was initiated on cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy, demonstrating a striking response. Cyclophosphamide 29-45 DNA damage inducible transcript 3 Homo sapiens 89-93 26986862-11 2016 We describe a case of therapy-related T/myeloid mixed phenotype acute leukemia following rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone R-CHOP chemotherapy for primary cutaneous diffuse large B-cell lymphoma DLBCL. Cyclophosphamide 100-116 DNA damage inducible transcript 3 Homo sapiens 161-165 26960952-4 2016 The patient was then treated with 8 cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) therapy, which resulted in histological and functional improvement of her salivary glands. Cyclophosphamide 65-81 DNA damage inducible transcript 3 Homo sapiens 48-52 27073670-1 2016 The cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) regimen is considered to be a standard treatment for non-Hodgkin"s lymphoma (NHL). Cyclophosphamide 4-20 DNA damage inducible transcript 3 Homo sapiens 65-69 28352766-9 2016 After the case was treated by cyclophosphamide pirarubicin vindesine dexamethasone (CHOP) chemotherapy for six courses, her clinical symptoms were partially alleviated, while CT showed progression disease. Cyclophosphamide 30-46 DNA damage inducible transcript 3 Homo sapiens 84-88 27039799-1 2016 BACKGROUND: A combination of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is one of the most effective front-line therapies to treat B-cell non-Hodgkin"s lymphoma (NHL). Cyclophosphamide 42-58 DNA damage inducible transcript 3 Homo sapiens 104-108 26315113-1 2015 Treatment with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) has greatly improved clinical outcomes in patients with diffuse large B-cell lymphoma (DLBCL) compared with CHOP. Cyclophosphamide 30-46 DNA damage inducible transcript 3 Homo sapiens 92-96 26458444-2 2015 The current standard therapy for DLBCL is R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) therapy, which allows many patients to achieve disease cure. Cyclophosphamide 61-77 DNA damage inducible transcript 3 Homo sapiens 44-48 26315113-1 2015 Treatment with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) has greatly improved clinical outcomes in patients with diffuse large B-cell lymphoma (DLBCL) compared with CHOP. Cyclophosphamide 30-46 DNA damage inducible transcript 3 Homo sapiens 206-210 26376594-2 2015 We present a 64-year-old man who was treated with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone) chemoimmunotherapy for mantle cell lymphoma and developed purulent meningitis, probably caused by Leuconostoc sp. Cyclophosphamide 73-89 DNA damage inducible transcript 3 Homo sapiens 52-56 26370464-1 2015 BACKGROUND: The regimen of cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) is an efficient treatment of non-Hodgkin"s lymphoma (NHL). Cyclophosphamide 27-43 DNA damage inducible transcript 3 Homo sapiens 89-93 25666327-4 2015 We present a 52-year-old male with lymphoma who was treated with R-CHOP (R: Rituximab; C: Cyclophosphamide; H: Doxorubicin; O: Vincristine; P: Prednisone). Cyclophosphamide 90-106 DNA damage inducible transcript 3 Homo sapiens 67-71 25675909-1 2015 BACKGROUND: Although the combination of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is considered standard therapy for diffuse large B-cell lymphoma (DLBCL), patterns of use and the impact of R-CHOP on survival in patients aged >80 years are less clear. Cyclophosphamide 51-67 DNA damage inducible transcript 3 Homo sapiens 113-117 25869285-7 2015 Anthracycline-based regimens such as cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) remain the standard first-line treatment choice for systemic ALCL, but in many patients with ALK- ALCL, it is ineffective, and thus it is often followed by consolidative autologous stem cell transplantation. Cyclophosphamide 37-53 DNA damage inducible transcript 3 Homo sapiens 97-101 25648098-1 2015 PURPOSE: Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is the standard chemotherapy in diffuse large B-cell lymphoma (DLBCL) patients. Cyclophosphamide 24-40 DNA damage inducible transcript 3 Homo sapiens 86-90 25675909-1 2015 BACKGROUND: Although the combination of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is considered standard therapy for diffuse large B-cell lymphoma (DLBCL), patterns of use and the impact of R-CHOP on survival in patients aged >80 years are less clear. Cyclophosphamide 51-67 DNA damage inducible transcript 3 Homo sapiens 229-233 25635435-1 2015 BACKGROUND: Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly prolonged event-free survival in first-line chemotherapy for patients with diffuse large B-cell lymphoma (DLBCL). Cyclophosphamide 42-58 DNA damage inducible transcript 3 Homo sapiens 102-106 26056479-7 2015 The patient underwent cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regime of chemotherapy and achieved a complete remission after four cycles. Cyclophosphamide 22-38 DNA damage inducible transcript 3 Homo sapiens 82-86 25881228-4 2015 METHODS: First, B-cell cancer cell lines were tested successively for resistance towards the chemotherapeutic components of R-CHOP: cyclophosphamide (C), doxorubicin (H), and vincristine (O). Cyclophosphamide 132-148 DNA damage inducible transcript 3 Homo sapiens 126-130 26687958-2 2015 Although it has limited efficacy, cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) therapy is widely used for treatment of de-novo peripheral T-cell lymphoma. Cyclophosphamide 34-50 DNA damage inducible transcript 3 Homo sapiens 94-98 25430047-1 2015 This study aimed to clarify the association between the TP53 rs1625895 polymorphism and the efficiency of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) therapy in 106 patients with diffuse large B cell lymphoma (DLBCL). Cyclophosphamide 125-141 DNA damage inducible transcript 3 Homo sapiens 108-112 24612334-1 2014 OBJECTIVES: Chemoimmunotherapy with cyclophosphamide, doxorubicin, vincristine, prednisolone, and rituximab (R-CHOP) is the standard of care for patients with diffuse large B-cell lymphoma (DLBCL). Cyclophosphamide 36-52 DNA damage inducible transcript 3 Homo sapiens 111-115 26137775-13 2015 The most widely used and most effective is the combination Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (CHOP). Cyclophosphamide 59-75 DNA damage inducible transcript 3 Homo sapiens 118-122 26334344-1 2015 INTRODUCTION: R-CHOP immunochemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) is a standard first-line treatment for diffuse large B-cell lymphoma (DLBCL). Cyclophosphamide 52-68 DNA damage inducible transcript 3 Homo sapiens 16-20 25323007-2 2014 Although patient outcomes have significantly improved to a greater than 40% cure rate by the combinatorial cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy, which is widely used, resistance to the CHOP regimen continues to pose a problem in managing or curing DLBCL. Cyclophosphamide 107-123 DNA damage inducible transcript 3 Homo sapiens 166-170 25323007-2 2014 Although patient outcomes have significantly improved to a greater than 40% cure rate by the combinatorial cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy, which is widely used, resistance to the CHOP regimen continues to pose a problem in managing or curing DLBCL. Cyclophosphamide 107-123 DNA damage inducible transcript 3 Homo sapiens 226-230 25337281-5 2014 The patient was treated with 6 courses of CHOP therapy (cyclophosphamide, doxorubicin, vincristine, and prednisolone), which resulted in complete remission (CR). Cyclophosphamide 56-72 DNA damage inducible transcript 3 Homo sapiens 42-46 25054764-7 2014 R-CHOP chemotherapy regimen (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) is the most widely accepted treatment. Cyclophosphamide 40-56 DNA damage inducible transcript 3 Homo sapiens 2-6 25878913-3 2015 The patient received cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) with rituximab and had excellent results. Cyclophosphamide 21-37 DNA damage inducible transcript 3 Homo sapiens 81-85 25229255-2 2014 Improvements in overall survival have been observed with the introduction of rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), however, prognostic markers are still needed. Cyclophosphamide 107-123 DNA damage inducible transcript 3 Homo sapiens 169-173 25197420-5 2014 The patient was treated with chemotherapeutic regimens-CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone). Cyclophosphamide 61-77 DNA damage inducible transcript 3 Homo sapiens 55-59 24180329-4 2014 Subanalysis of patients receiving cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) +- rituximab showed higher predictive power for both PFS (HR 2.75, 95% confidence interval [CI] 1.24-6.11, p = 0.01) and OS (HR 3.33, 95% CI 1.15-9.63, p = 0.02). Cyclophosphamide 34-50 DNA damage inducible transcript 3 Homo sapiens 93-97 22972488-1 2013 PURPOSE: Treatment of non-Hodgkin lymphoma (NHL) with cyclophosphamide, vincristine, doxorubicin and prednisone (CHOP) is known to be associated with a significant risk of febrile neutropenia (FN) of up to 50% [Osby et al. Cyclophosphamide 54-70 DNA damage inducible transcript 3 Homo sapiens 113-117 24395281-9 2014 Combination immunochemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) regimen improved both MALT lymphoma and PLE, whereas rituximab monotherapy was not successful. Cyclophosphamide 47-63 DNA damage inducible transcript 3 Homo sapiens 111-115 24143112-1 2013 Fludarabine-based regimens and CHOP (doxorubicin, cyclophosphamide, vincristine, prednisone)-like regimens with or without rituximab are the most common treatment modalities for indolent lymphoma. Cyclophosphamide 50-66 DNA damage inducible transcript 3 Homo sapiens 31-35 23137070-3 2013 Patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) had significantly superior survival rates. Cyclophosphamide 33-49 DNA damage inducible transcript 3 Homo sapiens 94-98 23615461-1 2013 BACKGROUND: Dose intensification with a combination of cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) every 2 weeks improves outcomes in patients older than 60 years with diffuse large B-cell lymphoma compared with CHOP every 3 weeks. Cyclophosphamide 55-71 DNA damage inducible transcript 3 Homo sapiens 117-121 23615461-1 2013 BACKGROUND: Dose intensification with a combination of cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) every 2 weeks improves outcomes in patients older than 60 years with diffuse large B-cell lymphoma compared with CHOP every 3 weeks. Cyclophosphamide 55-71 DNA damage inducible transcript 3 Homo sapiens 236-240 24989286-9 2014 After 2 cycles of treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone(R-CHOP), the images of increasing metabolic activity in subcutaneous soft tissue gap disappeared, but the partial increasing metabolism focus could be observed in soft tissue of left knee hollow. Cyclophosphamide 44-60 DNA damage inducible transcript 3 Homo sapiens 106-110 24493716-1 2014 PURPOSE: R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) is standard care for aggressive B-cell lymphoma. Cyclophosphamide 32-48 DNA damage inducible transcript 3 Homo sapiens 11-15 24724408-3 2014 The current standard of care for DLBCL is CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone) combined with rituximab, anti-CD20 antibody, allowing many patients to achieve disease cure. Cyclophosphamide 61-77 DNA damage inducible transcript 3 Homo sapiens 42-46 23636313-7 2013 Activation of the PI3K/AKT/mTOR pathway was related to poor disease outcome in DLBCL patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) but not in those treated with rituximab-CHOP. Cyclophosphamide 107-123 DNA damage inducible transcript 3 Homo sapiens 167-171 23846384-2 2013 The BM infiltration and the condition of the MF improved following CHOP therapy (cyclophosphamide hydrate, doxorubicin hydrochloride, vincristine sulfate, and prednisolone). Cyclophosphamide 81-105 DNA damage inducible transcript 3 Homo sapiens 67-71 24649228-2 2013 The reported 5-year overall survival for patients with localized nasal NKTCL treated with cyclophosphamide, hydroxydaunorubicin, oncovin and prednisone (CHOP) is <50%. Cyclophosphamide 90-106 DNA damage inducible transcript 3 Homo sapiens 153-157 23578722-1 2013 BACKGROUND: Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) has become the standard of care for elderly patients with diffuse large B-cell lymphoma. Cyclophosphamide 50-66 DNA damage inducible transcript 3 Homo sapiens 112-116 23166041-2 2013 The CHOP chemotherapy regimen, which includes cyclophosphamide, doxorubicin, vincristine and prednisone, has been used previously to treat other types of lymphomas. Cyclophosphamide 58-74 DNA damage inducible transcript 3 Homo sapiens 4-8 23053189-1 2013 R-CHOP chemotherapy composed of rituximab, cyclophosphamide, adriamycin, vincristine, and prednisolone which might increase the risk of Pneumocystis pneumonia in patients with non-Hodgkin lymphoma. Cyclophosphamide 43-59 DNA damage inducible transcript 3 Homo sapiens 2-6 23267908-5 2012 The malignant lymphoma patient was treated by cyclophosphamide+doxorubicin+vincristine+prednisolone(CHOP) with rituximab. Cyclophosphamide 46-62 DNA damage inducible transcript 3 Homo sapiens 100-104 24200545-8 2013 The patient received R-CHOP therapy (cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab) with good response. Cyclophosphamide 37-53 DNA damage inducible transcript 3 Homo sapiens 23-27 23996885-4 2013 We describe a patient with follicular lymphoma treated with R-CHOP scheme (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) who had pulmonary symptoms during chemotherapy which were diagnosed as rituximab-induced interstitial pneumonia. Cyclophosphamide 86-102 DNA damage inducible transcript 3 Homo sapiens 62-66 23814970-2 2012 Standard chemotherapy is CHOP regimen (cyclophosphamide, doxorubicin, vincristine and prednisone). Cyclophosphamide 39-55 DNA damage inducible transcript 3 Homo sapiens 25-29 22752193-1 2012 The combination chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) plus rituximab is the standard treatment for patients with primary gastric diffuse large B cell lymphoma (DLBCL). Cyclophosphamide 34-50 DNA damage inducible transcript 3 Homo sapiens 96-100 22983648-0 2012 Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in the treatment of stage IE/IIE extranodal natural killer/T cell lymphoma, nasal type: 13-year follow-up in 135 patients. Cyclophosphamide 0-16 DNA damage inducible transcript 3 Homo sapiens 60-64 23267962-13 2012 Cyclophosphamide+doxorubicin+vincristine+prednisolone(CHOP) with rituximab therapy was performed. Cyclophosphamide 0-16 DNA damage inducible transcript 3 Homo sapiens 54-58 22759738-4 2012 SUMMARY: Rituximab administered as induction or maintenance therapy in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly prolonged event-free survival. Cyclophosphamide 88-104 DNA damage inducible transcript 3 Homo sapiens 148-152 22721383-1 2012 R (rituximab)-CHOP (cyclophosphamide, adriamycin, vincristin, and prednisone) is given to outpatients with CD20-positive lymphoma as a standard treatment. Cyclophosphamide 20-36 DNA damage inducible transcript 3 Homo sapiens 14-18 22333190-12 2012 The patient was treated with chemotherapy (CHOP: cyclophosphamide, hydroxydaunorbicin, vincristine, and predonisone), and the lung tumor disappeared. Cyclophosphamide 49-65 DNA damage inducible transcript 3 Homo sapiens 43-47 22035416-1 2012 The prognosis of patients with peripheral T-cell lymphoma (PTCL) treated with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP) is poor, but their laboratory prognostic parameters had not previously been evaluated. Cyclophosphamide 78-94 DNA damage inducible transcript 3 Homo sapiens 136-140 22865806-4 2012 A brain biopsy confirmed the diagnosis of intravascular B-cell lymphoma and he was treated with CHOP chemotherapy (cyclophosphamide, hydroxydaunorubicin, vincristine and prednisolone). Cyclophosphamide 115-131 DNA damage inducible transcript 3 Homo sapiens 96-100 21460380-3 2012 The combination chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) with addition of etoposide (CHOEP) has in other patient groups been shown to be effective. Cyclophosphamide 34-50 DNA damage inducible transcript 3 Homo sapiens 93-97 22260632-4 2012 The patient initially received 6 cycles of chemotherapy with CHOP regimen (cyclophosphamide, vincristine, adriamycin, prednisone), but his symptoms did not disappear. Cyclophosphamide 75-91 DNA damage inducible transcript 3 Homo sapiens 61-65 22260632-9 2012 CHOP-R chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab) was then administered, resulting in partial response of the disease with pancytopenia and suppression of cellular immunity. Cyclophosphamide 21-37 DNA damage inducible transcript 3 Homo sapiens 0-4 23323070-8 2012 The association of this antibody to the cyclophosphamide, hydroxydaunorubicin, oncovin and prednisolone (CHOP) regimen has increased overall survival of diffuse large B-Cell lymphoma and follicular lymphoma patients by 20%. Cyclophosphamide 40-56 DNA damage inducible transcript 3 Homo sapiens 105-109 22997596-2 2012 We present the results of a long-term followup of two patients who were diagnosed with PRL and treated with cyclophosphamide, adriamycin, vincristine, prednisolone and rituximab (CHOP + R) regimen. Cyclophosphamide 108-124 DNA damage inducible transcript 3 Homo sapiens 179-183 22864129-5 2012 Combination chemotherapy composed of cyclophosphamide, vincristine, doxorubicin and prednisolone (CHOP) was effective for polyneuropathy as well as for lymphoma. Cyclophosphamide 37-53 DNA damage inducible transcript 3 Homo sapiens 98-102 21864040-1 2012 In the rituximab era, several large studies have suggested that full-dose rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) might be the best treatment for patients with diffuse large B-cell lymphoma (DLBCL) aged 60 years and older. Cyclophosphamide 89-105 DNA damage inducible transcript 3 Homo sapiens 150-154 21931035-1 2011 PURPOSE: Rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is one of the most effective front-line therapies to treat indolent B-cell lymphoma. Cyclophosphamide 24-40 DNA damage inducible transcript 3 Homo sapiens 86-90 22586509-2 2011 The cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) treatment regimen has been the standard of care for more than 20 years. Cyclophosphamide 4-20 DNA damage inducible transcript 3 Homo sapiens 64-68 22586511-1 2011 Chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) has long been a standard treatment for lymphoma. Cyclophosphamide 18-34 DNA damage inducible transcript 3 Homo sapiens 78-82 22586511-2 2011 Improvements to the efficacy of this regimen can be made by increasing the doses of doxorubicin and cyclophosphamide, as in the chemotherapeutic regimen of doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone (ACVBP), and by reducing the standard dosing interval, as seen with the CHOP-14 regimen. Cyclophosphamide 100-116 DNA damage inducible transcript 3 Homo sapiens 296-300 23556105-7 2011 A prospective, multicenter, international phase II trial evaluating sequential treatment with rituximab and CHOP-based chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone) is ongoing and preliminary results have been promising. Cyclophosphamide 133-149 DNA damage inducible transcript 3 Homo sapiens 108-112 21747882-1 2011 BACKGROUND: The addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy (R-CHOP) has significantly improved clinical outcomes for patients with diffuse large B-cell lymphoma (DLBCL). Cyclophosphamide 41-57 DNA damage inducible transcript 3 Homo sapiens 101-105 22563154-3 2011 We report a patient with primary ovarian diffuse large B-cell lymphoma (DLBCL) and associated auto-immune hemolytic anemia (AIHA) who achieved complete remission after treatment with Rituximab-cyclophosphamide-doxorubicin-vincristine and prednisolone (R-CHOP) chemotherapy. Cyclophosphamide 193-209 DNA damage inducible transcript 3 Homo sapiens 254-258 21257672-1 2011 BACKGROUND: Rituximab plus combination chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is widely recommended for the treatment of aggressive B-cell lymphomas. Cyclophosphamide 57-73 DNA damage inducible transcript 3 Homo sapiens 119-123 21747882-1 2011 BACKGROUND: The addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy (R-CHOP) has significantly improved clinical outcomes for patients with diffuse large B-cell lymphoma (DLBCL). Cyclophosphamide 41-57 DNA damage inducible transcript 3 Homo sapiens 123-127 21482186-3 2011 We aimed to investigate the efficacy and safety of a decreased dose of CHOP (doxorubicin, cyclophosphamide, vincristine, and prednisone) chemotherapy with a conventional dose of rituximab in elderly patients with diffuse large B-cell lymphoma. Cyclophosphamide 90-106 DNA damage inducible transcript 3 Homo sapiens 71-75 21498532-1 2011 UNLABELLED: R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)-like chemotherapy is the standard therapy in aggressive B-cell lymphoma. Cyclophosphamide 31-47 DNA damage inducible transcript 3 Homo sapiens 14-18 21323512-1 2011 Development of resistance to the CHOP chemotherapeutic regimen (cyclophosphamide, doxorubicin, vincristine, prednisone) remains a major cause of treatment failure and mortality in approximately 40% of patients with diffuse large B-cell lymphoma (DLBCL). Cyclophosphamide 64-80 DNA damage inducible transcript 3 Homo sapiens 33-37 22099932-7 2011 AIM: The aim of the study was to evaluate the clinical risk stratification models including the age adjusted International prognostic index (aaIPI), patients profile and dose intensity (DI) of Cyclophosphamide and Doxorubicin as effective tools for predicting the outcome and prognosis of our DLBCL patients treated with first line CHOP regimen. Cyclophosphamide 193-209 DNA damage inducible transcript 3 Homo sapiens 332-336 20354901-4 2011 The patient was treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) with rituximab, and a dramatic improvement of renal function was noticed after two weeks of treatment. Cyclophosphamide 29-45 DNA damage inducible transcript 3 Homo sapiens 89-93 20830228-1 2010 BACKGROUND/AIMS: Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy (R-CHOP) has improved survival in patients with diffuse large B-cell lymphoma (DLBCL) and weakened the prognostic power of the international prognostic index (IPI). Cyclophosphamide 32-48 DNA damage inducible transcript 3 Homo sapiens 107-111 22454706-5 2011 He received chemotherapy with CHOP regimen (cyclophosphamide, adriamycin, vincristine and prednisolone) resulting in reduction in lesion size leaving a phthysical eyeball and a ptotic lid. Cyclophosphamide 44-60 DNA damage inducible transcript 3 Homo sapiens 30-34 21030533-3 2010 DLBCL is associated with an aggressive natural history, but it can be cured with combination chemotherapy regimens like cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), which has been the mainstay of therapy for several decades. Cyclophosphamide 120-136 DNA damage inducible transcript 3 Homo sapiens 180-184 21050687-8 2010 The classic CHOP protocol (combination of doxorubicin-cyclophosphamide-vincristine-prednisone) does not have satisfactory results and survival remains poor, especially in patients with underlying RCD. Cyclophosphamide 54-70 DNA damage inducible transcript 3 Homo sapiens 12-16 21103206-3 2010 We describe a 51-year-old man with jejunal B-cell lymphoma who developed recurrent episodes of ischemic colitis following chemotherapy with cyclophosphamide, vincristine, doxorubicine and prednisolone plus rituximab (R-CHOP). Cyclophosphamide 140-156 DNA damage inducible transcript 3 Homo sapiens 219-223 20842604-8 2010 TREATMENT AND COURSE: After 6 cycles of rituximab, cyclophosphamide, doxorubicin, vincristin and prednisolone (R-CHOP), an early relapse developed which was treated with rituximab, ifosphamid, methotrexate and etoposide. Cyclophosphamide 51-67 DNA damage inducible transcript 3 Homo sapiens 113-117 20198460-1 2010 The addition of rituximab to cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) improved the outcome of patients with diffuse large B-cell lymphoma (DLBCL). Cyclophosphamide 29-45 DNA damage inducible transcript 3 Homo sapiens 88-92 19850640-2 2010 cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) is recognized as the standard chemotherapy regimen and the addition of rituximab to B-cell subtypes has been shown to significantly improve treatment outcomes. Cyclophosphamide 0-16 DNA damage inducible transcript 3 Homo sapiens 59-63 19861575-1 2010 BACKGROUND: The addition of rituximab to CHOP (R-CHOP; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy improves outcome in patients with diffuse large B-cell lymphoma (DLBCL). Cyclophosphamide 61-77 DNA damage inducible transcript 3 Homo sapiens 41-45 20371444-2 2010 PATIENTS AND METHODS: We retrospectively analyzed 46 patients all treated with standard chemotherapy ([CHOP] cyclophosphamide/doxorubicin/vincristine/prednisone-like); of these, 16 received rituximab. Cyclophosphamide 109-125 DNA damage inducible transcript 3 Homo sapiens 103-107 20610938-1 2010 We report the case of a patient with non-Hodgkin"s lymphoma who, during chemotherapy according to the r-CHOP schedule (rituximab-cyclophosphamide-doxorubicin-vincristine and prednisone), showed a hepatic flare with jaundice. Cyclophosphamide 129-145 DNA damage inducible transcript 3 Homo sapiens 104-108 20016232-2 2009 Conventional chemotherapy (CHOP: cyclophosphamide, doxorubicin, vincristine, prednisone) seems unsatisfactory, so modifications of CHOP are used to improve the efficacy. Cyclophosphamide 33-49 DNA damage inducible transcript 3 Homo sapiens 27-31 20214520-1 2010 For more than 25 years, the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) was considered the "gold standard" for the treatment of aggressive lymphomas, 90% of which are diffuse large B-cell lymphomas (DLBCLs). Cyclophosphamide 43-59 DNA damage inducible transcript 3 Homo sapiens 102-106 20195409-0 2010 Severe pulmonary adverse effects in lymphoma patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus rituximab. Cyclophosphamide 67-83 DNA damage inducible transcript 3 Homo sapiens 127-131 20195409-1 2010 BACKGROUND/AIMS: The aim of our study was to determine the incidence and clinical features of severe pulmonary complications in patients receiving cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or rituximab plus CHOP (R-CHOP) as the initial treatment for lymphoma. Cyclophosphamide 147-163 DNA damage inducible transcript 3 Homo sapiens 207-211 20195409-1 2010 BACKGROUND/AIMS: The aim of our study was to determine the incidence and clinical features of severe pulmonary complications in patients receiving cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or rituximab plus CHOP (R-CHOP) as the initial treatment for lymphoma. Cyclophosphamide 147-163 DNA damage inducible transcript 3 Homo sapiens 237-243 20302754-12 2010 Ten patients received adjuvant chemotherapy with the regimen of CHOP (cyclophosphamide + epirubicin + vincristine + prednisone) after the operation. Cyclophosphamide 70-86 DNA damage inducible transcript 3 Homo sapiens 64-68 20016232-2 2009 Conventional chemotherapy (CHOP: cyclophosphamide, doxorubicin, vincristine, prednisone) seems unsatisfactory, so modifications of CHOP are used to improve the efficacy. Cyclophosphamide 33-49 DNA damage inducible transcript 3 Homo sapiens 131-135 19861288-1 2009 Treatment with cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) has been considered as the standard therapy for diffuse large B-cell lymphoma (DLBCL) for more than 20 years. Cyclophosphamide 15-31 DNA damage inducible transcript 3 Homo sapiens 76-80 19293492-7 2009 Treatment with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus etoposide established complete remission. Cyclophosphamide 15-31 DNA damage inducible transcript 3 Homo sapiens 75-79 19776000-1 2009 BACKGROUND: The results of CHOP-21 (cyclophosphamide, doxorubicin, vincristine and prednisone given every 21 days) for the treatment of aggressive B-cell lymphoma have recently been improved by the addition of rituximab and by increasing the dose density. Cyclophosphamide 36-52 DNA damage inducible transcript 3 Homo sapiens 27-31 18620786-2 2009 In phase 3 clinical trials, giving rituximab with cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) every 3 weeks (R-CHOP-21) has been associated with improved survival, without increased toxicity, in all patient groups studied. Cyclophosphamide 50-66 DNA damage inducible transcript 3 Homo sapiens 110-114 18620786-2 2009 In phase 3 clinical trials, giving rituximab with cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) every 3 weeks (R-CHOP-21) has been associated with improved survival, without increased toxicity, in all patient groups studied. Cyclophosphamide 50-66 DNA damage inducible transcript 3 Homo sapiens 133-137 19204436-5 2009 There was significant improvement in response to the first 4 cycles of CHOP chemotherapy (consisting of cyclophosphamide, doxorubicin, vincristine and prednisolone) instituted, but then there were features of relapse. Cyclophosphamide 104-120 DNA damage inducible transcript 3 Homo sapiens 71-75 18502831-1 2008 Chemotherapy with alemtuzumab and the combination of cyclophosphamide, adriamycin, oncovin, and prednisone (CHOP) has become experimental trial therapy for aggressive T-cell lymphoma. Cyclophosphamide 53-69 DNA damage inducible transcript 3 Homo sapiens 108-112 18937075-3 2008 We describe the clinical course of hypopituitarism as a complication of IVL, successfully treated with immunochemotherapy (cyclophosphamide/doxorubicin/vincristine/prednisone-CHOP) plus Rituximab anti-CD20 humanized antibody). Cyclophosphamide 123-139 DNA damage inducible transcript 3 Homo sapiens 175-179 18303033-1 2008 BACKGROUND: A prospective, single-arm, open-label, nonrandomized phase II combination chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus radioimmunotherapy trial was conducted to evaluate the efficacy and safety in untreated elderly diffuse large B-cell lymphoma (DLBCL) patients. Cyclophosphamide 104-120 DNA damage inducible transcript 3 Homo sapiens 164-168 18760704-1 2008 The concurrent use of rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) has established the utility of chemoimmunotherapy for the treatment of aggressive non-Hodgkin"s lymphoma (NHL). Cyclophosphamide 37-53 DNA damage inducible transcript 3 Homo sapiens 99-103 18420078-5 2008 Following combined chemotherapy with rituximab and mini-CHOP (cyclophosphamide, adriamycin, oncovin and prednisone), complete remission was obtained rapidly, with no relapse at two years. Cyclophosphamide 62-78 DNA damage inducible transcript 3 Homo sapiens 56-60 18583880-1 2008 The objective of the current study was to investigate the treatment outcomes for the use of cyclophosphamide, adriamycin, vincristine, and prednisolone (CHOP) chemotherapy in adult patients with hemophagocytic lymphohistiocytosis (HLH). Cyclophosphamide 92-108 DNA damage inducible transcript 3 Homo sapiens 153-157 18712992-4 2008 The patient was treated with 6 courses of CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone). Cyclophosphamide 61-77 DNA damage inducible transcript 3 Homo sapiens 42-46 18306483-2 2008 Shortness of breath developed following the 5th course of Rituximab-CHOP chemotherapy (cyclophosphamide, Vincristine, Doxorubicin, Prednisolone). Cyclophosphamide 87-103 DNA damage inducible transcript 3 Homo sapiens 68-72 18381103-3 2008 The addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy (R-CHOP regimen) improves the response rate, progression-free survival (PFS), and overall survival (OS) in diffuse large B-cell lymphoma (DLBCL). Cyclophosphamide 29-45 DNA damage inducible transcript 3 Homo sapiens 89-93 18388378-7 2008 The patient received five cycles of a cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) regimen which resulted in the regression in her skin lesions and constitutional symptoms. Cyclophosphamide 38-54 DNA damage inducible transcript 3 Homo sapiens 97-101 18162120-1 2008 Immunochemotherapy with cyclophosphamide, adriamycin, vincristine, prednisone and rituximab (R-CHOP) is the standard treatment in non-immunosuppressed patients with diffuse large B-cell lymphoma (DLBCL), but its adequacy has not been definitively established in patients with human immunodeficiency virus (HIV)-related lymphoma. Cyclophosphamide 24-40 DNA damage inducible transcript 3 Homo sapiens 95-99 17591563-3 2007 Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy has been the standard systemic therapy for this disease with a cure rate of 40% to 50%, although, more recently, the addition of rituximab has been shown in phase III trials to confer a significant survival benefit in both older and younger patients. Cyclophosphamide 0-16 DNA damage inducible transcript 3 Homo sapiens 60-64 18284716-1 2007 Among the strategies developed to improve results in patients with diffuse large B-cell lymphoma, increasing the dose of CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone) regimen (dose-intense regimen) and decreasing the duration of cycles (dose-dense regimen) or doing both had been proposed before the rituximab era. Cyclophosphamide 127-143 DNA damage inducible transcript 3 Homo sapiens 121-125 17939339-5 2007 A CT scan performed following three cycles of chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) showed that the mass had nearly disappeared. Cyclophosphamide 64-80 DNA damage inducible transcript 3 Homo sapiens 126-130 18226581-1 2008 BACKGROUND: Cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) is used to treat patients with non-Hodgkin lymphoma. Cyclophosphamide 12-28 DNA damage inducible transcript 3 Homo sapiens 74-78 17562513-5 2007 We present multidetector CT (MDCT) findings in a case of Hodgkin disease status one month post-chemotherapy (CHOP protocol; cyclophosphamide, doxorubicin, vincristine, prednisone) that presented with acute lower GIS bleeding. Cyclophosphamide 124-140 DNA damage inducible transcript 3 Homo sapiens 109-113 16997373-10 2007 The patient was treated with six cycles of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP). Cyclophosphamide 43-59 DNA damage inducible transcript 3 Homo sapiens 102-106 17530014-5 2007 A combination of rituximab plus chemotherapy, rituximab+cyclophosphamide+doxorubicin+vincristine+prednisolone (R-CHOP), has the highest efficacy ever described with any chemotherapy in DLBCL and FL. Cyclophosphamide 56-72 DNA damage inducible transcript 3 Homo sapiens 113-117 17488991-5 2007 However, response rate is usually lower in elderly patients compared with young patients, even if the patients are treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen. Cyclophosphamide 132-148 DNA damage inducible transcript 3 Homo sapiens 192-196 17361405-2 2007 Six cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone-21 (CHOP-21) with rituximab (R-CHOP-21) achieved an event free survival after 3 years of > 90% in patients with a very good prognosis (IPI 0, without bulk). Cyclophosphamide 14-30 DNA damage inducible transcript 3 Homo sapiens 77-81 17085516-4 2006 The management of patients with AIDS-related NHL with either infusional chemotherapy or CHOP-like regimens (cyclophosphamide, doxorubicin, vincristine and prednisolone) achieves response and survival rates approaching those observed in the general population. Cyclophosphamide 108-124 DNA damage inducible transcript 3 Homo sapiens 88-92 17027654-4 2006 Second, the discovery of a potential curative combination of drugs, including cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), for use in advanced disease could eradicate micro-metastatic disease in patients with LD. Cyclophosphamide 78-94 DNA damage inducible transcript 3 Homo sapiens 138-142 16609067-1 2006 The precise mechanism of rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (R-CHOP) therapy in diffuse large B-cell lymphoma (DLBCL) is not fully elucidated. Cyclophosphamide 40-56 DNA damage inducible transcript 3 Homo sapiens 95-99 16985248-1 2006 BACKGROUND: Follicular lymphoma is considered incurable, although cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy can induce sequential remissions. Cyclophosphamide 66-82 DNA damage inducible transcript 3 Homo sapiens 126-130 16788784-5 2006 The standard chemotherapy for aggressive non-Hodgkin"s lymphomas is the CHOP regimen consisting of cyclophosphamide, doxorubicin, vincristine, and prednisone. Cyclophosphamide 99-115 DNA damage inducible transcript 3 Homo sapiens 72-76 16840195-1 2006 Recently, the cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) regimen plus rituximab (R-CHOP) have been used widely to treat patients with follicular lymphoma. Cyclophosphamide 14-30 DNA damage inducible transcript 3 Homo sapiens 73-77 16943530-2 2006 This conclusion is mainly derived from patients with mixed international prognostic index (IPI) risk profiles treated with CHOP-like therapy (cyclophosphamide, doxorubicin, vincristine, and prednisone). Cyclophosphamide 142-158 DNA damage inducible transcript 3 Homo sapiens 123-127 16925484-1 2006 For more than 25 years, the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) was considered the gold standard for the treatment of aggressive lymphomas, 90% of which are diffuse, large B-cell lymphomas (DLBCLs). Cyclophosphamide 43-59 DNA damage inducible transcript 3 Homo sapiens 102-106 16640819-3 2006 In this regard, we report an 80-year-old patient with follicular grade 3 non-Hodgkin"s lymphoma who developed a fatal interstitial pneumonitis related to treatment with a rituximab/CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone) regimen. Cyclophosphamide 187-203 DNA damage inducible transcript 3 Homo sapiens 181-185 16753869-3 2006 We used clinical information obtained during pretreatment evaluation to develop a predictive model for severe neutropenia in the first cycle of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy. Cyclophosphamide 144-160 DNA damage inducible transcript 3 Homo sapiens 203-207 16416337-1 2006 The addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) has been shown to improve the outcome in all age groups with newly diagnosed diffuse large B-cell lymphoma (DLBCL). Cyclophosphamide 29-45 DNA damage inducible transcript 3 Homo sapiens 89-93